Catalyst Wire Dossier Catalyst Wire Dossier

Glycopyrronium bromide (NVA237)

glycopyrronium bromide · Novartis
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Glycopyrronium bromide (NVA237), covering 2012-07-27 to 2012-07-27. Get the full timeline:

Most recent: Clinical Trial Update: 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

See pricing